keyword
MENU ▼
Read by QxMD icon Read
search

Febuxostat

keyword
https://www.readbyqxmd.com/read/28521802/identification-of-chronic-kidney-disease-patient-characteristics-influencing-the-renoprotective-effects-of-febuxostat-therapy-a-retrospective-follow-up-study
#1
Akinori Yamaguchi, Makoto Harada, Yosuke Yamada, Koji Hashimoto, Yuji Kamijo
BACKGROUND: The ability of antihyperuricemic therapy to exert renoprotective effects in patients with chronic kidney disease (CKD) is controversial. In the present study, we studied patient characteristics that may mask favorable impact of antihyperuricemic therapy on the progression of CKD. METHODS: This was a single-center, retrospective, follow-up study. One-hundred and seventy-eight CKD patients with hyperuricemia who received febuxostat therapy were included in this study...
May 18, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28503330/febuxostat-attenuates-renal-damage-besides-exerting-hypouricemic-effect-in-streptozotocin-induced-diabetic-rats
#2
Jianmin Ran, Gang Xu, Huixuan Ma, Hailing Xu, Yan Liu, Rongshao Tan, Ping Zhu, Jun Song, Gancheng Lao
Aim. In this study, we aimed to investigate the effects of febuxostat, a novel inhibitor of xanthine oxidase (XO), on renal damage in streptozotocin- (STZ-) induced diabetic rats. Methods. Diabetes was induced by the intraperitoneal injection of STZ in male Sprague-Dawley rats. Sham-injected rats served as controls. The control and diabetic rats were treated with and without febuxostat for 8 weeks, respectively. Fasting blood and 24-h urine samples were collected every 4 weeks. Rat livers were extracted for detecting gene expression, content, and bioactivity of XO...
2017: International Journal of Nephrology
https://www.readbyqxmd.com/read/28485997/prophylaxis-of-acute-flares-when-initiating-febuxostat-for-chronic-gouty-arthritis-in-a-real-world-clinical-setting
#3
Jinquan Yu, Qian Qiu, Liuqin Liang, Xiuyan Yang, Hanshi Xu
OBJECTIVE: Flare prophylaxis is recommended during urate-lowering therapy (ULT) despite lack of proven benefit especially when initiating febuxostat. We investigated if colchicine or steroids administration during initiation of febuxostat for chronic gouty arthritis reduces the frequency and/or severity of acute gout flares. METHODS: Patients with confirmed diagnosis of gout starting febuxostat were retrospectively studied. Frequency, severity, and length of flares were analyzed...
May 9, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28463849/effect-of-febuxostat-on-the-endothelial-dysfunction-in-hemodialysis-patients-a-randomized-placebo-controlled-double-blinded-study
#4
Mona Alshahawey, Sara Mahmoud Shahin, Tamer Wahid Elsaid, Nagwa Ali Sabri
BACKGROUND: Endothelial dysfunction is an important risk factor for cardiovascular diseases to occur in end-stage renal disease patients. Febuxostat, being a novel xanthine oxidase inhibitor, is apparently having a beneficial role in improving the endothelial dysfunction; however, data among hemodialysis patients are still limited. METHODS: A prospective, placebo-controlled, block-randomized, double-blinded study was carried out to evaluate the effect of oral febuxostat on the endothelial dysfunction in hemodialysis patients...
2017: American Journal of Nephrology
https://www.readbyqxmd.com/read/28460508/-effect-of-febuxostat-on-epithelial-to-mesenchymal-transition-of-kidney-tubules-serum-interleukin-6-and-transforming-growth-factor-%C3%AE-1-in-hyperuricemic-rats
#5
Z M Lin, R S Zhang, C X Fan, Y L Liang, L Li, L Zhao, J C Qu, X Xu, H Y Zhao, X N Liu, K S Zhu
Objective: To observe the effect of febuxostat on epithelial-to-mesenchymal transition (EMT) of kidney tubules and the levels of serum IL-6 nad transforming growth factor (TGF)β(1) in hyperuricemic rats. Methods: Forty male SD rats were divided into 4 groups: normal control group (NC group), oteracil potassium group (OP group), oteracil potassium with febuxostat group (OF group) and oteracil potassium with benzbromarone group (OB group). Each group had 10 rats and balanced in body weights. To induce hyperuricemia, rats were given oteracil potassium by gastric gavage once a day for eight weeks...
May 1, 2017: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/28458354/previous-dosage-of-allopurinol-is-a-strong-determinant-of-febuxostat-efficacy
#6
Hiroyoshi Koide, Daiki Hira, Masayuki Tsujimoto, Yurie Katsube, Tetsuya Minegaki, Takashi Uzu, Yoshito Ikeda, Shin-Ya Morita, Kohshi Nishiguchi, Tomohiro Terada
Febuxostat has currently played pivotal role in the treatment of hyperuricemia, but there is little comprehensive information for the determinants of individual difference in efficacy of febuxostat. Therefore, the present study, a retrospective investigation, was carried out to analyze the effects of patient characteristics on the efficacy of febuxostat. A total of 225 patients who were continuously prescribed the same dose of febuxostat for 8-12 weeks from the initial therapy were enrolled in the present study...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28455534/xanthine-oxidase-inhibition-by-febuxostat-attenuates-stress-induced-hyperuricemia-glucose-dysmetabolism-and-prothrombotic-state-in-mice
#7
Maimaiti Yisireyili, Motoharu Hayashi, Hongxian Wu, Yasuhiro Uchida, Koji Yamamoto, Ryosuke Kikuchi, Mohammad Shoaib Hamrah, Takayuki Nakayama, Xian Wu Cheng, Tadashi Matsushita, Shigeo Nakamura, Toshimitsu Niwa, Toyoaki Murohara, Kyosuke Takeshita
Chronic stress is closely linked to the metabolic syndrome, diabetes, hyperuricemia and thromboembolism, but the mechanisms remain elusive. We reported recently that stress targets visceral adipose tissue (VAT), inducing lipolysis, low-grade inflammation with production of inflammatory adipokines, metabolic derangements such as insulin resistance, and prothrombotic state. In the present study, we hypothesized the involvement of VAT xanthine oxidoreductase (XOR), a source of reactive oxygen species (ROS) and uric acid (UA) in the above processes...
April 28, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28430170/current-management-of-gout-practical-messages-from-2016-eular-guidelines
#8
George Nuki, Michael Doherty, Pascal Richette
The European League Against Rheumatism published updated recommendations for the management of gout in 2016, comprising 3 overarching principles and 11 key recommendations for clinical practice. Patient education about the pathophysiology of gout and its comorbidities, as well as the existence of effective treatments are important, and understanding the principles of managing acute attacks and eliminating urate crystals by lifelong lowering of the serum urate (SU) below a target level are essential. Advice about lifestyle, diet, weight, and other risk factors, as well as the need to screen for, and manage, comorbidities is emphasized...
April 28, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/28425024/lesinurad-a-review-in-hyperuricaemia-of-gout
#9
Emma D Deeks
Lesinurad (Zurampic(®)) is an oral selective inhibitor of the URAT1 and OAT4 uric acid (UA) transporters of the kidney, via which it inhibits UA reabsorption and thus increases renal UA excretion and lowers serum UA (sUA) levels. Lesinurad 200 mg once daily is indicated for use in combination with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in adults with gout who have not achieved target sUA levels with an XOI alone. Approval was based on three 12-month phase 3 trials that evaluated lesinurad in combination with allopurinol in adults with gout inadequately responsive to allopurinol (CLEAR 1 and 2) and in combination with febuxostat in adults with tophaceous gout (CRYSTAL)...
April 19, 2017: Drugs & Aging
https://www.readbyqxmd.com/read/28408434/renal-and-vascular-effects-of-uric-acid-lowering-in-normouricemic-patients-with-uncomplicated-type-1-diabetes
#10
Yuliya Lytvyn, Ronnie Har, Amy Locke, Vesta Lai, Derek Fong, Andrew Advani, Bruce A Perkins, David Z I Cherney
Higher plasma uric acid (PUA) levels are associated with lower GFR and higher blood pressure (BP) in patients with type 1 diabetes (T1D). Our aim was to determine the impact of PUA lowering on renal and vascular function in patients with uncomplicated T1D.T1D patients (n=49) were studied under eu- and hyperglycemic conditions at baseline and after PUA lowering with febuxostat (FBX) for 8 weeks. Healthy controls (HC) were studied under normoglycemic conditions (n=24). PUA, GFR (inulin), effective renal plasma flow (ERPF, paraaminohippurate), BP and hemodynamic responses to an infusion of angiotensin II (assessment of intrarenal RAAS) were measured pre- and post-FBX...
April 13, 2017: Diabetes
https://www.readbyqxmd.com/read/28379501/cardiovascular-effects-of-urate-lowering-therapies-in-patients-with-chronic-gout-a-systematic-review-and-meta-analysis
#11
Tony Zhang, Janet E Pope
Objectives.: To determine if urate-lowering treatment (ULT) in gout can reduce cardiovascular (CV) outcomes. Methods.: Randomized trials were searched for treatment with ULT in gout. Eligible trials had to report CV safety of a ULT. Potential medications included allopurinol, febuxostat, pegloticase, rasburicase, probenecid, benzbromarone, sulphinpyrazone, losartan, fenofibrate and sodium-glucose linked transporter 2 inhibitors. Results.: A total of 3084 citations were found, with 642 duplicates...
March 30, 2017: Rheumatology
https://www.readbyqxmd.com/read/28365572/cost-effectiveness-analysis-for-genotyping-before-allopurinol-treatment-to-prevent-severe-cutaneous-adverse-drug-reactions
#12
Ching-Hua Ke, Wen-Hung Chung, Yen-Hsia Wen, Yaw-Bin Huang, Hung-Yi Chuang, You-Lin Tain, Yu-Ching Lily Wang, Cheng-Chih Wu, Chien-Ning Hsu
OBJECTIVE: Patients with an HLA-B*58:01 allele have an increased risk of developing severe cutaneous adverse drug reactions (SCAR) when treated with allopurinol. Although one-off pharmacogenetic testing may prevent life-threatening adverse drug reactions, testing prior to allopurinol initiation incurs additional costs. The study objective was to evaluate the cost-effectiveness of HLA-B*58:01 screening compared with using other available urate-lowering agents (ULA). METHODS: A decision-analytical model was used to compare direct medical costs and effectiveness [including lifetime saved, quality-adjusted life-yrs (QALY) gained] in treating new patients with the following options: (1) genetic screening followed by allopurinol prescribing for noncarriers of HLAB* 58:01, (2) prescribing benzbromarone without screening, (3) prescribing febuxostat without screening, and (4) prescribing allopurinol without screening...
April 1, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28335813/tumor-lysis-syndrome-in-an-extraskeletal-osteosarcoma-a-case-report-and-review-of-the-literature
#13
Vito Emanuele Catania, Michele Vecchio, Michele Malaguarnera, Roberto Madeddu, Giulia Malaguarnera, Saverio Latteri
BACKGROUND: This case report describes a spontaneous tumor lysis syndrome due to a rare solid tumor. CASE PRESENTATION: A 65-year-old white woman had tumor lysis syndrome, which represent a dangerous oncological emergency. This syndrome occurs usually with a hematological tumor, but in this case our patient had a solid tumor, which was a rare extraskeletal osteosarcoma, localized in her pelvic region. She also had lung metastases and bilateral hydronephrosis. After spontaneous tumor lysis syndrome, she had acute renal insufficiency, which was treated with hemodialysis and successively with rasburicase, Kayexalate (sodium polystyrene sulfonate), and febuxostat...
March 24, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28330320/xanthine-oxidase-inhibitory-and-antioxidant-potential-of-indian-muscodor-species
#14
Neha Kapoor, Sanjai Saxena
Xanthine oxidase is a key enzyme responsible for hyperuricemia, a pre-disposing factor for Gout and oxidative stress-related diseases. Only two clinically approved xanthine oxidase inhibitors Allopurinol and Febuxostat are currently used for treatment of hyperuricemia. However, owing to their side effects there is a need for new non-purine-based selective inhibitors of xanthine oxidase. In the process of exploring novel xanthine oxidase inhibitors and anti-oxidants, we screened the culture filtrate of 07 novel species of Muscodor, a sterile endophytic fungi isolated from Cinnamomum and Aegle marmelos...
December 2016: 3 Biotech
https://www.readbyqxmd.com/read/28302902/risk-of-febuxostat-associated-myopathy-in-patients-with-ckd
#15
Chung-Te Liu, Chun-You Chen, Chien-Yi Hsu, Po-Hsun Huang, Feng-Yen Lin, Jaw-Wen Chen, Shing-Jong Lin
BACKGROUND AND OBJECTIVES: Febuxostat, a nonpurine xanthine oxidase inhibitor, is widely used to treat hyperuricemia. Although febuxostat-associated rhabdomyolysis was reported in some patients with CKD, the association between CKD and febuxostat-associated myopathy remains uncertain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Our retrospective cohort study included 1332 patients using febuxostat in Taipei Medical University-Wanfang Hospital from February of 2014 to January of 2016...
May 8, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28291044/advances-in-urate-lowering-therapy-time-to-revisit-high-dose-febuxostat
#16
Aryeh M Abeles
No abstract text is available yet for this article.
May 2017: American Journal of Therapeutics
https://www.readbyqxmd.com/read/28257823/ameliorative-effects-of-sildenafil-and-or-febuxostat-on-doxorubicin-induced-nephrotoxicity-in-rats
#17
Ali Khames, Marwa M Khalaf, Amany M Gad, Ola M Abd El-Raouf
Sildenafil and febuxostat protect against doxorubicin-induced nephrotoxicity; however the exact mechanism remains to be elucidated. The effect of sildenafil and febuxostat on doxorubicin-induced nephrotoxicity in rats was studied. Male rats were subdivided into nine groups. The 1st group served as normal control, the 2nd group received dimethylsulfoxide 50% (DMSO), the 3rd group received doxorubicin (3.5mg/kg, i.p.), twice weekly for 3 weeks. The next 3 groups received sildenafil (5mg/kg; p.o.), febuxostat (10mg/kg; p...
February 28, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28255339/use-of-febuxostat-in-the-management-of-gout-in-the-united-kingdom
#18
REVIEW
Arabella Waller, Kelsey M Jordan
Gout is the most common cause of inflammatory arthritis worldwide. Despite clinical cure being achievable and multiple evidence-based guidelines having been published, the incidence and prevalence continues to increase and the condition remains undertreated. Concerns regarding allopurinol have limited its use in those with renal impairment. Febuxostat, a novel xanthine oxidase inhibitor requiring no dose adjustment in mild-moderate renal impairment was launched in the United Kingdom (UK) in 2010. We review published data on the efficacy, safety and tolerability of febuxostat and provide an opinion on its place in the management of gout in the UK in the context of other published guidelines...
February 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/28246893/crystal-arthritides-gout-and-calcium-pyrophosphate-arthritis-part%C3%A2-3-treatment
#19
REVIEW
S Schlee, L C Bollheimer, T Bertsch, C C Sieber, P Härle
The treatment of gout is based on several principles. Symptom control and termination of the inflammatory process are important early goals, whereas the urate level should be lowered in the long term to prevent further gout attacks and complications. The non-pharmacological approach is based on individually informing the patient on dietary measures and changes of life style. Besides physical measures, such as cold applications on the affected joint, various medications are available for treatment of an acute gout attack...
February 28, 2017: Zeitschrift Für Gerontologie und Geriatrie
https://www.readbyqxmd.com/read/28223818/an-evidence-based-review-on-urate-lowering-treatments-implications-for-optimal-treatment-of-chronic-hyperuricemia
#20
REVIEW
Marilisa Bove, Arrigo Francesco Giuseppe Cicero, Maddalena Veronesi, Claudio Borghi
Several studies suggest that chronic hyperuricemia, the main precursor of gout, is involved in the pathogenesis of different systemic disorders that affect cardiovascular and renal systems, such as hypertension, obesity, hypercholesterolemia, atherosclerosis, metabolic syndrome, chronic heart failure, and chronic kidney disease. Recent epidemiological evidence has shown an increasing trend in the prevalence of hyperuricemia and gout in the Western world: a number of population-based studies estimate a prevalence of up to 21% for hyperuricemia and 1%-4% for gout...
2017: Vascular Health and Risk Management
keyword
keyword
8954
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"